Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.56 |
| ▸ | AR | P10275 | 5/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9818896 | 1.00 | PBRM1 (0.56) | PBRM1ARSIGMAR1HTR1AMAOB | |
| SCHEMBL19584927 | 0.87 | PBRM1 (0.53) | PBRM1ARSIGMAR1HTR1AMAOB | |
| SCHEMBL9819034 | 0.84 | SIGMAR1 (0.49) | ARSIGMAR1HTR1AMAOBABCB1 | |
| SCHEMBL11377847 | 0.83 | SIGMAR1 (0.66) | ARSIGMAR1HTR1AMAOBABCB1 | |
| SCHEMBL19585579 | 0.82 | PBRM1 (0.51) | PBRM1ARSIGMAR1HTR1AMAOB | |
| SCHEMBL9819081 | 0.81 | SIGMAR1 (0.46) | ARSIGMAR1HTR1AMAOBABCB1 | |
| SCHEMBL15537413 | 0.80 | PBRM1 (0.66) | PBRM1ARMAOBMAOAABCB1 | |
| SCHEMBL10368729 | 0.80 | HRH3 (0.41) | ARSIGMAR1HTR1AGRM2MAPT | |
| SCHEMBL15589544 | 0.78 | PBRM1 (0.58) | PBRM1ARSIGMAR1HTR1AMAOB | |
| SCHEMBL15537839 | 0.78 | PBRM1 (0.62) | PBRM1ARMAOBMAOAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407410-B2 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2019-09-10 | — | — | US | disclosed |
| US-10407410-B2 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2019-09-10 | — | — | US | disclosed |
| US-20190127351-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| US-20190127351-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| EP-3455215-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017195113-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017195113-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-11-16 | — | — | WO | disclosed |
| US-9242973-B2 | Chromane compounds | COMENTIS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242973-B2 | Chromane compounds | COMENTIS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150225386-A1 | CHROMANE COMPOUNDS | COMENTIS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-8975415-B2 | Chromane compounds | COMENTIS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975415-B2 | Chromane compounds | COMENTIS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140179695-A1 | CHROMANE COMPOUNDS | COMENTIS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179695-A1 | CHROMANE COMPOUNDS | COMENTIS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2013181202-A2 | CHROMANE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2013-12-05 | — | — | WO | disclosed |
| WO-2011072064-A1 | S PIRO [CHROMAN - 4, 4 ' - IMIDAZOL] ONES AS BETA - SECRETASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| EP-0230379-B1 | CHROMAN- AND THIOCHROMAN-4-ACETIC ACIDS USEFUL IN THE TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407410-B2 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | TYMP, TYMS, DUT | PBRM1 1538/4885AR 2471/4885SIGMAR1 4189/4885 |
| US-20140179695-A1 | CHROMANE COMPOUNDS | BACE1, BACE2, APP | PBRM1 2533/4885AR 3824/4885SIGMAR1 4602/4885 |
| US-20150225386-A1 | CHROMANE COMPOUNDS | BACE1, BACE2, APP | PBRM1 1992/4885AR 3923/4885SIGMAR1 4084/4885 |
| US-20190127351-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | TYMP, TYMS, DUT | PBRM1 1538/4885AR 2471/4885SIGMAR1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.